Definitive Contract W81XWH22C0030
Award Date
4/5/22
Potential Completion Date
12/4/25
Potential Value
$23M
Federal Agency
Defense Health Agency
Awardee
Ophirex, Inc.
Ultimate Awardee
Not listed
NAICS Category
541715 - Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
Federal Contract Vehicle
Set-Aside Type
Total Small Business
Extent Competed
Full and Open Competition after exclusion of sources
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Corte Madera, CA 94925, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
1
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
SBIR Program Phase III Action
Primary Consortia Member
Not listed
Similar Awards
This federal contract award, valued at $29,999,425.00, was granted by the Defense Health Agency (DHA) to Ophirex, Inc., a for-profit small business, for the "BROAD SPECTRUM SNAKEBITE ANTIDOTE: CONCLUSION OF ORAL PRODUCT DEVELOPMENT" project under the Small Business Innovation Research (SBIR) Program Phase III. The contract is an Other Transaction Agreement (OTA) and does not have a set-aside designation. Ophirex, Inc. will be responsible for completing the oral product development...
This is a firm fixed price, definitive contract awarded by the Department of the Army Medical Command to Ophirex, Inc., a small business, under the Small Business Innovation Research (SBIR) Program Phase I. The contract, valued at $148,509.12, is for the development of a broad-spectrum envenomation treatment. Ophirex, a for-profit organization, has previously received SBIR Phase II and III awards from the Department of the Army Medical Command and the Defense Health Agency for related research...
Ophirex, Inc. has been awarded a firm fixed price definitive contract valued at $1,299,779 by the Department of the Army Medical Command. This contract is a Small Business Innovation Research Program Phase II award to further develop Ophirex's intravenous snakebite antidote varespladib. Specifically, the contract aims to improve recovery time following snakebite through metalloprotease inhibition. As a total small business set aside, this award will support Ophirex's continued medical research...
This is a $3,849.30 firm fixed-price purchase order awarded by the National Institute of Allergy and Infectious Diseases (NIAID), a civilian agency within the Department of Health and Human Services. The contract is for the product "COBRA VENOM" and was awarded to Sigma-Aldrich, Inc., a foreign-owned, for-profit organization that provides laboratory supplies, chemicals, and materials to support scientific research and development across multiple federal agencies. The award is not...
The Department of the Army Medical Command awarded Ophirex, Inc. a $10.6 million definitive contract to support research and development efforts for a COVID-19 treatment under the Small Business Innovation Research Program Phase III. The prime contractor will conduct work at its place of performance in Corte Madera, California from June 2020 through September 2023 under the firm fixed price contract, which has a total small business set aside designation. Specifically, Ophirex will perform...
This is a $55,754.44 firm fixed-price delivery order contract awarded by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp's Corporate Office division. The contract is to provide ANTIVENIN MICRURUS FULVIUS, a pharmaceutical product, with a period of performance through October 17, 2024. Amerisourcebergen is a major supplier of pharmaceutical and medical products to the federal government, leveraging its extensive supply chain network. This contract is likely part of...
This is a $1,099,999.92 Firm Fixed Price SBIR Phase II contract awarded by the Joint PEO Chemical and Biological Defense, a component of the U.S. Army, to Consegna Pharma Inc., a small disadvantaged business. The contract is for the development of a long-duration opioid overdose antagonist. This award follows a prior $167,421 SBIR Phase I contract Consegna received from the Army for additional pharmaceutical research and development. Consegna has also received several grants from the National...
The Department of the Army Medical Command awarded a $293,790 firm fixed price purchase order to Tryco Incorporated for the delivery of Polyserp Snake Antivenom and Poly-M Snake Antivenom. The solicitation sought bids to supply 36 boxes of Polyserp Snake Antivenom and 6 boxes of Poly-M Snake Antivenom for delivery to locations in Germany by December 29, 2021. Offerors were required to demonstrate compliance with FDA standards for these products and an ability to transport the goods...
This is a $150,000.00 Firm Fixed Price contract awarded by the U.S. Army Medical Command (MEDCOM) to Medenvvet Laboratories Inc., a Service Disabled Veteran Owned Small Business (SDVOSB) corporation. The contract was awarded under the Small Business Innovation Research (SBIR) Program Phase I, and is for research and development of a "Biodegradable Vector Control System." The contract has a performance period ending on April 5, 2020 and was set aside exclusively for small businesses.
This is a $149,962.80 firm-fixed-price contract awarded by the U.S. Army Medical Command (MEDCOM) to Hedgefog Research Inc., a small business manufacturer headquartered in San Pedro, California. The contract is for Phase I research and development under the Small Business Innovation Research (SBIR) program, with an ultimate completion date of April 29, 2017. The contract is designated as a total small business set-aside. Hedgefog Research Inc. specializes in developing advanced technologies...